Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced that members of the Company’s leadership team will be participating at the following upcoming investor conferences in March.
COLUMBUS, Ohio--(BUSINESS WIRE)-- Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that members of the Company’s leadership team will be participating at the following upcoming investor conferences in March:
| Cowen 42nd Annual Virtual Health Care Conference | ||
| Dates: | March 7-9, 2022 | |
| Format: | 1x1 investor meetings | |
| Oppenheimer Fireside Chat | ||
| Date: | March 14, 2022 | |
| Time: | 11:00 a.m. Eastern Time | |
| Title: | “AAV-based Gene Therapy: Navigating Regulatory and CMC Landscape” | |
| Presenters: | Timothy J. Miller, Ph.D., Chief Executive Officer of Forge Biologics | |
| RA Session, II, Chief Executive Officer of Taysha Gene Therapies | ||
| Rachel Potter, Ph.D., Head of Gene Therapy Research at Sarepta Therapeutics | ||
| Moderators: | Kevin DeGeeter, Senior Analyst, Biotechnology and Diagnostics | |
| Hartaj Singh, Senior Analyst, Biotechnology | ||
| Oppenheimer 32nd Annual Virtual Healthcare Conference | ||
| Dates: | March 15-17, 2022 | |
| Format: | 1x1 investor meetings | |
| Date: | March 17, 2022 | |
| Time: | 10:40 a.m. Eastern Time | |
| Format: | Company presentation | |
| Presenter: | Timothy J. Miller, Ph.D., CEO, President and Co-Founder of Forge Biologics | |
Dr. Miller’s Oppenheimer company presentation will be delivered via live webcast and may be accessed for 90 days by visiting Forge’s Events website at https://www.forgebiologics.com/news/#events.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 200,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220307005504/en/
Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com
Business Development
Magdalena Tyrpien
Senior Vice President, Head of Business Development
BD@forgebiologics.com
Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com
Investor Relations
Christina Perry
Senior Vice President, Finance and Investor Relations
Investors@forgebiologics.com
Source: Forge Biologics
View this news release online at:
http://www.businesswire.com/news/home/20220307005504/en
